Mandate

Vinge has advised Vimian Group in connection with its rights issue

March 12, 2024

Vinge has advised Vimian Group AB (publ) in connection with a partly guaranteed rights issue which will provide Vimian with issue proceeds of SEK 1,633 billion before deduction of transaction costs.

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. At Vimian, one believes that every animal deserves the best available care. Vimian brings pioneering businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners.

Vinge’s team consisted of Dain Hård NevonenLinnéa Sellström, Anna Svensson, Michaela Ådén and Alexander Rüdén.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025